Inhibition of osteoblast activity by zoledronic acid

Bibliographic Details
Main Author: Basso, Fernanda Gonçalves
Publication Date: 2013
Other Authors: Turrioni, Ana Paula Silveira [UNESP], Hebling, Josimeri [UNESP], Costa, Carlos Alberto de Souza [UNESP]
Format: Article
Language: eng
Source: Repositório Institucional da UNESP
Download full: http://dx.doi.org/10.1590/S1676-24442013000500011
http://hdl.handle.net/11449/109922
Summary: INTRODUCTION: Patients treated with nitrogen-containing bisphosphonates, such as zoledronic acid (ZA), have frequently shown oral bone exposure areas, termed osteonecrosis. In addition, these patients may also present low repair and regeneration potential, mainly after tooth extractions. These side-effects caused by bisphosphonates may be due to their inhibitory effects on oral mucosa and local bone cells. OBJECTIVE: To evaluate the effects of ZA on the mineralization capacity of cultured osteoblasts. MATERIALS AND METHODS: Human immortalized osteoblasts (SaOs-2) were grown in plain culture medium (Dulbecco's Modified Eagle Medium [DMEM] + 10% fetal bovine serum [FBS]) in wells of 24-well plates. After 48-hour incubation, the plain DMEM was replaced by a solution with ZA at 5 µM which was maintained in contact with cells for seven, 14 or 21 days. After these periods, cells were evaluated regarding alkaline phosphatase (ALP) activity and mineral nodule formation (alizarin red). Data were statistically analyzed by Mann-Whitney test, at 5% of significance level. RESULTS: ZA caused significant reduction on ALP activity and mineral nodules formation by cultured osteoblasts in all evaluated periods (p < 0.05). CONCLUSION: These data indicate that ZA causes inhibition on the osteogenic phenotype of cultured human osteoblasts, which, in turn, may reduce bone repair in patients subjected to ZA therapy.
id UNSP_0c16eff367066dfd9bfc79c9a082d20a
oai_identifier_str oai:repositorio.unesp.br:11449/109922
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Inhibition of osteoblast activity by zoledronic acidInibição da atividade de osteoblastos expostos ao ácido zoledrônicoosteonecrosereparomineralizaçãoosteoblastososteonecrosisrepairmineralizationosteoblastsINTRODUCTION: Patients treated with nitrogen-containing bisphosphonates, such as zoledronic acid (ZA), have frequently shown oral bone exposure areas, termed osteonecrosis. In addition, these patients may also present low repair and regeneration potential, mainly after tooth extractions. These side-effects caused by bisphosphonates may be due to their inhibitory effects on oral mucosa and local bone cells. OBJECTIVE: To evaluate the effects of ZA on the mineralization capacity of cultured osteoblasts. MATERIALS AND METHODS: Human immortalized osteoblasts (SaOs-2) were grown in plain culture medium (Dulbecco's Modified Eagle Medium [DMEM] + 10% fetal bovine serum [FBS]) in wells of 24-well plates. After 48-hour incubation, the plain DMEM was replaced by a solution with ZA at 5 µM which was maintained in contact with cells for seven, 14 or 21 days. After these periods, cells were evaluated regarding alkaline phosphatase (ALP) activity and mineral nodule formation (alizarin red). Data were statistically analyzed by Mann-Whitney test, at 5% of significance level. RESULTS: ZA caused significant reduction on ALP activity and mineral nodules formation by cultured osteoblasts in all evaluated periods (p < 0.05). CONCLUSION: These data indicate that ZA causes inhibition on the osteogenic phenotype of cultured human osteoblasts, which, in turn, may reduce bone repair in patients subjected to ZA therapy.INTRODUÇÃO: Pacientes em tratamento com bisfosfonatos, sobretudo com os nitrogenados, como o ácido zoledrônico (AZ), têm apresentado áreas de exposição de tecido ósseo na cavidade oral, caracterizadas como osteonecrose. Essas áreas apresentam limitada capacidade de reparo, principalmente após exodontias. Esses efeitos podem ser resultado do efeito inibitório causado por esse tipo de medicamento sobre as células da mucosa e do tecido ósseo local. OBJETIVO: Avaliar o efeito do AZ sobre a capacidade de mineralização de osteoblastos in vitro. MATERIAIS E MÉTODOS: Foi utilizada uma linhagem celular de osteoblastos humanos (SaOs-2). As células foram cultivadas em meio de cultura completo (Dulbecco's Modified Eagle Medium [DMEM] + 10% de soro fetal bovino [SFB]). Após 48 horas de incubação, o DMEM completo foi substituído por um novo DMEM sem SFB, ao qual foram adicionados 5 µM de AZ. Essa solução foi mantida em contato com as células por sete, 14 ou 21 dias. Após esse período, as células foram avaliadas quanto à atividade de fosfatase alcalina (ALP) e à produção de nódulos de mineralização (alizarin red). Os dados foram submetidos ao teste estatístico de Mann-Whitney, considerando nível de significância de 5%. RESULTADOS: A exposição das células ao AZ causou redução significativa na atividade de ALP e na formação de nódulos mineralizados em todos os períodos avaliados (p < 0,05). CONCLUSÃO: Esses resultados revelam que o AZ causa alteração inibitória no fenótipo osteogênico das células humanas em cultura, o que pode reduzir a capacidade de reparo do tecido ósseo após o contato com esse tipo de medicamento.Universidade Estadual de Campinas Faculdade de Odontologia de PiracicabaUNESP FOAr Program of Dental SciencesUNICAMP FOPUNESP FOAr Program of Dental SciencesSociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de CitopatologiaUniversidade Estadual de Campinas (UNICAMP)Universidade Estadual Paulista (Unesp)Basso, Fernanda GonçalvesTurrioni, Ana Paula Silveira [UNESP]Hebling, Josimeri [UNESP]Costa, Carlos Alberto de Souza [UNESP]2014-10-01T13:08:40Z2014-10-01T13:08:40Z2013-10-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article368-371application/pdfhttp://dx.doi.org/10.1590/S1676-24442013000500011Jornal Brasileiro de Patologia e Medicina Laboratorial. Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia, v. 49, n. 5, p. 368-371, 2013.1676-2444http://hdl.handle.net/11449/10992210.1590/S1676-24442013000500011S1676-24442013000500011S1676-24442013000500011.pdf4517484241515548SciELOreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengJornal Brasileiro de Patologia e Medicina Laboratorial0,143info:eu-repo/semantics/openAccess2025-04-18T09:41:14Zoai:repositorio.unesp.br:11449/109922Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462025-04-18T09:41:14Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Inhibition of osteoblast activity by zoledronic acid
Inibição da atividade de osteoblastos expostos ao ácido zoledrônico
title Inhibition of osteoblast activity by zoledronic acid
spellingShingle Inhibition of osteoblast activity by zoledronic acid
Basso, Fernanda Gonçalves
osteonecrose
reparo
mineralização
osteoblastos
osteonecrosis
repair
mineralization
osteoblasts
title_short Inhibition of osteoblast activity by zoledronic acid
title_full Inhibition of osteoblast activity by zoledronic acid
title_fullStr Inhibition of osteoblast activity by zoledronic acid
title_full_unstemmed Inhibition of osteoblast activity by zoledronic acid
title_sort Inhibition of osteoblast activity by zoledronic acid
author Basso, Fernanda Gonçalves
author_facet Basso, Fernanda Gonçalves
Turrioni, Ana Paula Silveira [UNESP]
Hebling, Josimeri [UNESP]
Costa, Carlos Alberto de Souza [UNESP]
author_role author
author2 Turrioni, Ana Paula Silveira [UNESP]
Hebling, Josimeri [UNESP]
Costa, Carlos Alberto de Souza [UNESP]
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual de Campinas (UNICAMP)
Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Basso, Fernanda Gonçalves
Turrioni, Ana Paula Silveira [UNESP]
Hebling, Josimeri [UNESP]
Costa, Carlos Alberto de Souza [UNESP]
dc.subject.por.fl_str_mv osteonecrose
reparo
mineralização
osteoblastos
osteonecrosis
repair
mineralization
osteoblasts
topic osteonecrose
reparo
mineralização
osteoblastos
osteonecrosis
repair
mineralization
osteoblasts
description INTRODUCTION: Patients treated with nitrogen-containing bisphosphonates, such as zoledronic acid (ZA), have frequently shown oral bone exposure areas, termed osteonecrosis. In addition, these patients may also present low repair and regeneration potential, mainly after tooth extractions. These side-effects caused by bisphosphonates may be due to their inhibitory effects on oral mucosa and local bone cells. OBJECTIVE: To evaluate the effects of ZA on the mineralization capacity of cultured osteoblasts. MATERIALS AND METHODS: Human immortalized osteoblasts (SaOs-2) were grown in plain culture medium (Dulbecco's Modified Eagle Medium [DMEM] + 10% fetal bovine serum [FBS]) in wells of 24-well plates. After 48-hour incubation, the plain DMEM was replaced by a solution with ZA at 5 µM which was maintained in contact with cells for seven, 14 or 21 days. After these periods, cells were evaluated regarding alkaline phosphatase (ALP) activity and mineral nodule formation (alizarin red). Data were statistically analyzed by Mann-Whitney test, at 5% of significance level. RESULTS: ZA caused significant reduction on ALP activity and mineral nodules formation by cultured osteoblasts in all evaluated periods (p < 0.05). CONCLUSION: These data indicate that ZA causes inhibition on the osteogenic phenotype of cultured human osteoblasts, which, in turn, may reduce bone repair in patients subjected to ZA therapy.
publishDate 2013
dc.date.none.fl_str_mv 2013-10-01
2014-10-01T13:08:40Z
2014-10-01T13:08:40Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S1676-24442013000500011
Jornal Brasileiro de Patologia e Medicina Laboratorial. Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia, v. 49, n. 5, p. 368-371, 2013.
1676-2444
http://hdl.handle.net/11449/109922
10.1590/S1676-24442013000500011
S1676-24442013000500011
S1676-24442013000500011.pdf
4517484241515548
url http://dx.doi.org/10.1590/S1676-24442013000500011
http://hdl.handle.net/11449/109922
identifier_str_mv Jornal Brasileiro de Patologia e Medicina Laboratorial. Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia, v. 49, n. 5, p. 368-371, 2013.
1676-2444
10.1590/S1676-24442013000500011
S1676-24442013000500011
S1676-24442013000500011.pdf
4517484241515548
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Jornal Brasileiro de Patologia e Medicina Laboratorial
0,143
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 368-371
application/pdf
dc.publisher.none.fl_str_mv Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia
publisher.none.fl_str_mv Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia
dc.source.none.fl_str_mv SciELO
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv repositoriounesp@unesp.br
_version_ 1834482665379594240